For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Oxybutynin - Overactive bladder (adults)
PAD Profile : Oxybutynin - Overactive bladder (adults)
Traffic Light Status
Status 1 of 3.
- Patches
Status 2 of 3.
- Modified release tablets
- Oral solution
- Tablets
Status 3 of 3.
- Intravesical
This drug/device has not yet been assessed for formulary status [for this indication] and is not currently on the APC work-plan.
This drug/device has not yet been evaluated by the Surrey Heartlands ICS Area Prescribing Committee (APC). As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined.
Before prescribing this drug/device it is recommended that clinicians contact their Medicines Optimisation team to discuss possible alternatives/options.
The APC will consider recommending the prescribing of this treatment upon submission of a formal request with its associated evidence. Clinicians can contact syheartlandsicb.APC@nhs.net if they wish to make a submission.
Guidelines
The following guidelines are available for this indication.
Other Drugs
- Darifenacin hydrobromide
- Flavoxate hydrochloride
- Propiverine hydrochloride
- Solifenacin
- Mirabegron
- Fesoterodine fumarate
- Trospium chloride
- Tolterodine
- Imipramine hydrochloride
Other Indications
No indications returned.
Additional Documents
Committee Recommendations
The APC supports patients in trialling a treatment break of their overactive bladder medicines.
A "Leaflet for trial of stopping anticholinergics" can be found in the documents section below.
Oxybutynin immediate-release and modified-release tablets are non-formulary. A switch from oxybutinin tablets to solifenacin is recommended (where appropriate).
Patients with swallowing difficulties
Solifenacin oral SUSPENSION 1mg/ml sugar free is the preferred treatment option.
Oxybutynin patches should be reserved for patients in whom an oral route is not suitable.
See Selection Tool for locally agreed OAB treatment options